TRAWSFYNYDD THERAPEUTICS RECEIVES APPROVAL FOR THE FIRST PATIENT TRIAL OF TRX01, A ONCE-DAILY PROTEASE INHIBITOR FOR THE TREATMENT OF COVID 19

ROCKVILLE, Md., Feb. 12, 2024 /PRNewswire/ — Trawsfynydd Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering antiviral treatments for respiratory viral diseases, today announced of a first-in-man clinical trial of the novel best-in-class COVID-19…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks